Adlai Nortye is a China-based, clinical-stage biopharmaceutical company focused on developing immuno-oncology medicines. The company announced the completion of nearly $100 million in a Series C round of financing. The article identifies the raise as a Series C but does not specify the financing instrument beyond that round type. No participating investors or syndicate details were disclosed in the article. The report also does not provide information on prior funding rounds, founding year, revenue, users, or intended use of proceeds. The financing announcement was reported as having been made on Monday. Adlai Nortye Biopharma is a Hangzhou, China–based clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer treatments with a primary concentration on immuno-oncology. Led by CEO Carsten Lu, the company is advancing a pipeline of more than 10 diverse product candidates. It has two clinical-stage immune-oncology programs: Reolysin, an intravenously delivered immuno-oncolytic virus for solid tumors, and AN0025, a first-in-class EP4 antagonist. Reolysin is ready to enter a Phase III study and has received FDA Fast Track designation to expedite development and review. AN0025 is currently in a global Phase Ib trial. The company recently strengthened its financial position by completing a $53M Series B financing.

Total raised

$153M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2020